Related Experiment Videos

Aromatase inhibition: translation into a successful therapeutic approach

Jürgen Geisler1, Per Eystein Lønning

  • 1Department of Medicine, Section of Oncology, Haukeland University Hospital, Bergen, Norway.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 20, 2005
PubMed

Insights

Novel third-generation aromatase inhibitors significantly improve breast cancer treatment by achieving over 98% aromatase inhibition. Translational research was key to developing these potent endocrine therapies.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Breast cancer treatment has advanced significantly with novel therapies.
  • Aromatase inhibitors are crucial for endocrine therapy in breast cancer.
  • Third-generation inhibitors represent a major leap in efficacy.

Purpose of the Study:

  • To summarize translational research behind third-generation aromatase inhibitors.
  • To highlight the development of potent aromatase inhibitors and inactivators.
  • To emphasize the importance of translational studies in cancer therapy.

Main Methods:

  • Evaluation of endocrine effects and clinical efficacy of aromatase inhibitors.
  • In vivo assessment of estrogen deprivation and aromatase inhibition.
  • Comparative analysis of first-, second-, and third-generation aromatase inhibitors.

Main Results:

  • Third-generation aromatase inhibitors (anastrozole, exemestane, letrozole) achieve > or =98% aromatase inhibition.
  • These compounds are highly potent, surpassing earlier generations.
  • Translational studies identified unique characteristics and efficacy.

Conclusions:

  • Third-generation aromatase inhibitors are a successful advancement in breast cancer therapy.
  • Translational research was vital for their clinical implementation.
  • Future research should focus on overcoming resistance mechanisms for improved endocrine therapy.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...